NEPH Form 4: Director reports 1,622-share grant and option holding

Rhea-AI Filing Summary

Nephros (NEPH) Form 4: A director reported acquiring 1,622 shares of common stock on 11/10/2025 at $0, held directly following the transaction.

The reporting person also holds a stock option to buy 13,229 shares at $4.49, expiring 08/11/2035. The option vests as to 4,410 shares on 6/16/25, 4,410 shares on 6/16/26, and 4,409 shares on 6/16/27.

Insider Trade Summary

Net Buyer: 1,622 shares

Net Buy 2 txns

Insider Nettis Lisa Marie

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,622	$0.00	$0.00
holding	Stock Option (right to buy)	--	--	--

Holdings After Transaction: Common Stock — 1,622 shares (Direct); Stock Option (right to buy) — 13,229 shares (Direct)

Footnotes (1)

1. F1. This option vests as to 4,410 shares on each of 6/16/25 and 6/16/26 and 4,409 options vest on 6/16/27.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/13/2025 - 05:00 PM Learn about SEC filing dates

FAQ

What insider transaction did NEPH report on Form 4?

A director acquired 1,622 shares of common stock on 11/10/2025 at $0, held directly.

What stock options does the NEPH director hold?

A stock option to buy 13,229 shares at an exercise price of $4.49, expiring 08/11/2035.

What is the vesting schedule for the NEPH option grant?

Vests as to 4,410 shares on 6/16/25 and 6/16/26, and 4,409 shares on 6/16/27.

How many NEPH shares are directly owned after the transaction?

The form shows 1,622 shares directly owned following the reported transaction.

Who signed the NEPH Form 4?

Signed by Edward Peilen as Attorney-in-Fact for Lisa Nettis pursuant to a previously filed Power of Attorney.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nettis Lisa Marie

(Last) (First) (Middle)

C/O NEPHROS, INC., 380 LACKAWANNA PLACE

(Street)

SOUTH ORANGE NJ 07079

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEPHROS INC [ NEPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/10/2025		A		1,622	A	$0	1,622	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.49							(1)	08/11/2035	Common Stock	13,229		13,229	D

Explanation of Responses:

1. This option vests as to 4,410 shares on each of 6/16/25 and 6/16/26 and 4,409 options vest on 6/16/27.

	Edward Peilen as Attorney-in-Fact for Lisa Nettis pursuant to Power of Attorney filed previously.	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.